Amgen To Study Aranesp Anemia Indication In Heart Failure Patients
Executive Summary
Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure
You may also be interested in...
Amgen Looks To U.S. Contracting Strategies To Head Off European Biosimilars
Amgen is bringing U.S. contracting strategies to Europe as part of its efforts to stave off competition from biosimilars, Exec VP-Commercial Operations George Morrow said during the firm's recent annual business review
Amgen Looks To U.S. Contracting Strategies To Head Off European Biosimilars
Amgen is bringing U.S. contracting strategies to Europe as part of its efforts to stave off competition from biosimilars, Exec VP-Commercial Operations George Morrow said during the firm's recent annual business review
Procrit Shows Benefits Over Aranesp In Anemia Patient Study
Cancer patients with chemotherapy-induced anemia who are treated with Procrit (epoetin alfa) experience a higher increase in hemoglobin levels than those treated with Aranesp (darbepoetin alfa), according to a study in the September issue of The Oncologist.